LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Aandelen Lijst・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Gesloten

8.19 -3.42

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.04

Max

8.48

Belangrijke statistieken
By Trading Economics
Inkomsten	4.2M -23M
Winstmarge	-2,027.003
Werknemers	83
EBITDA	6.6M -23M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+61.29% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	41M 628M
Vorige openingsprijs	11.61
Vorige sluitingsprijs	8.19

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 dec 2025, 16:42 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

12 dec 2025, 23:49 UTC

Acquisities, Fusies, Overnames

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dec 2025, 22:52 UTC

Marktinformatie

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dec 2025, 22:32 UTC

Winsten

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 dec 2025, 20:45 UTC

Winsten

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dec 2025, 20:41 UTC

Marktinformatie

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dec 2025, 20:20 UTC

Marktinformatie

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dec 2025, 19:23 UTC

Winsten

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dec 2025, 18:35 UTC

Acquisities, Fusies, Overnames

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dec 2025, 18:33 UTC

Acquisities, Fusies, Overnames

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dec 2025, 18:31 UTC

Marktinformatie

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dec 2025, 17:49 UTC

Winsten

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dec 2025, 17:34 UTC

Acquisities, Fusies, Overnames

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12 dec 2025, 17:33 UTC

Acquisities, Fusies, Overnames

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12 dec 2025, 17:33 UTC

Acquisities, Fusies, Overnames

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12 dec 2025, 17:32 UTC

Acquisities, Fusies, Overnames

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12 dec 2025, 17:31 UTC

Acquisities, Fusies, Overnames

Orange to Buy the Stake for EU4.25B in Cash

12 dec 2025, 17:24 UTC

Marktinformatie

Argentina Predicts Record Wheat Crop -- Market Talk

12 dec 2025, 17:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

12 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 dec 2025, 17:18 UTC

Marktinformatie

Winsten

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12 dec 2025, 17:09 UTC

Marktinformatie

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12 dec 2025, 17:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 dec 2025, 16:47 UTC

Marktinformatie

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

12 dec 2025, 16:39 UTC

Marktinformatie

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

12 dec 2025, 16:27 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

12 dec 2025, 16:15 UTC

Winsten

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

12 dec 2025, 15:35 UTC

Winsten

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dec 2025, 14:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

61.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.71 USD 61.29%

Hoogste 21 USD

Laagste 2 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ventyx Biosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.